Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

798 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G. Müller D, et al. Among authors: hallek m. Leuk Lymphoma. 2016 May;57(5):1130-9. doi: 10.3109/10428194.2015.1070151. Epub 2015 Nov 20. Leuk Lymphoma. 2016. PMID: 26584689
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Elter T, et al. Among authors: hallek m. J Clin Oncol. 2005 Oct 1;23(28):7024-31. doi: 10.1200/JCO.2005.01.9950. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145065 Clinical Trial.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group. Eichhorst BF, et al. Among authors: hallek m. Blood. 2006 Feb 1;107(3):885-91. doi: 10.1182/blood-2005-06-2395. Epub 2005 Oct 11. Blood. 2006. PMID: 16219797 Free article. Clinical Trial.
Fludarabine in chronic lymphocytic leukaemia.
Elter T, Hallek M, Engert A. Elter T, et al. Among authors: hallek m. Expert Opin Pharmacother. 2006 Aug;7(12):1641-51. doi: 10.1517/14656566.7.12.1641. Expert Opin Pharmacother. 2006. PMID: 16872267 Review.
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Eichhorst BF, et al. Among authors: hallek m. Br J Haematol. 2007 Jan;136(1):63-72. doi: 10.1111/j.1365-2141.2006.06382.x. Epub 2006 Nov 3. Br J Haematol. 2007. PMID: 17083342 Free article. Clinical Trial.
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M; German CLL Study Group. Eichhorst BF, et al. Among authors: hallek m. J Clin Oncol. 2007 May 1;25(13):1722-31. doi: 10.1200/JCO.2006.05.6929. Epub 2007 Mar 26. J Clin Oncol. 2007. PMID: 17389338 Clinical Trial.
798 results